Busra Nigdelioglu

Busra Nigdelioglu

Auto-generated profile, based on publicly available information

Busra Nigdelioglu

Department of Medical Oncology1, Ümraniye Eğitim ve Araştırma Hastanesi, Turkey

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2026 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
ABAyberk Bayramgil
Ayberk Bayramgil
TGTugce Kubra Gunes
Tugce Kubra Gunes
FAFatma Gulcicek Ayranci
Fatma Gulcicek Ayranci
DADuygu Yoruk Atik
Duygu Yoruk Atik
BNBusra Nigdelioglu
Busra Nigdelioglu
OKOzgecan Dulgar Kaya
Ozgecan Dulgar Kaya
Introduction/Background: Cholangiocarcinoma (CC) is a rare, aggressive cancer of the bile ducts with limited treatment advancements over recent decades. The five-year survival rate for CC remains low, around 10%, and even lower for advanced cases. Case Presentation: This case report discusses a 46-year-old woman with metastatic CC who achieved remarkable progression-free survival with regorafenib, a multikinase inhibitor typi-cally used in other cancers. After multiple lines of treatment, regorafenib was given as a 7th-line therapy. Despite initial intolerance requiring dose reduction, the patient achieved 22 months of progression-free survival (PFS) with stable disease and partial regression in some areas. Her response to regorafenib significantly exceeded typical outcomes in the literature, where PFS generally ranges from 3 to 4 months. This improvement may be attributed to an FGFR2 mutation identified via next-generation sequencing, which regorafenib may effec-tively target. Conclusion: This case suggests that patients with FGFR2 mutations might benefit from regorafenib, warranting further studies to explore this associationAs can be applied as a promising target gene to develop drug resistance and remedial efficacy.